THCA Therapeutics has completed Version 2 of the THCA PURE™ Oral Product Series.

The updated series provides a focused visual and technical overview of the company’s lead product concept for rheumatoid-arthritis research. It brings the product architecture, material strategy, manufacturing workflow, analytical controls, packaging direction and development status into one consistent communication format.

Version 2 is aligned with the current physically compartmentalized cap-in-softgel formulation. The concept consists of an inner hard capsule containing high-purity THCA isolate powder and an outer softgel containing hemp seed oil, without direct premixing of the two materials.

The Product Series also describes the intended progression from qualified raw-material supply and incoming quality verification through CDMO processing, capsule manufacture, inspection, analytical testing and protective packaging.

Its purpose is to support discussions with formulation specialists, CDMOs, laboratories, scientific advisors, investors and strategic partners while presenting the product concept in accordance with the THCA Therapeutics corporate identity.

THCA PURE™ Oral remains an investigational concept under development. Product manufacturability, stability, release, bioavailability, safety and efficacy have not yet been established.